Beta Cat Pharmaceuticals

Beta Cat Pharmaceuticals is developing compounds which modulate beta catenin and are in the translational phase. These compounds target beta catenin, the end result of seminal mutations in the APC/WNT pathway, and modulate it by degrading it in the cytoplasm, and denying it access to the nucleus, where it is believed to be highly oncologic and drive cancer growth as a cancer stem cell pathway.